Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3701
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? ; volume:8 ; number:1 ; day:18 ; month:4 ; year:2018 ; pages:1-3 ; date:12.2018
Cell & bioscience ; 8, Heft 1 (18.4.2018), 1-3, 12.2018
- Creator
-
Tang, Fei
- Contributor
-
Du, Xuexiang
Liu, Mingyue
Zheng, Pan
Liu, Yang
SpringerLink (Online service)
- DOI
-
10.1186/s13578-018-0229-z
- URN
-
urn:nbn:de:101:1-2018062522432418983345
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tang, Fei
- Du, Xuexiang
- Liu, Mingyue
- Zheng, Pan
- Liu, Yang
- SpringerLink (Online service)
Other Objects (12)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy